Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022

Rhea-AI Summary

Exagen Inc. (Nasdaq: XGN) will announce its financial results for the year and fourth quarter ended December 31, 2021, on March 22, 2022, after market close. The earnings call will be hosted by key executives, including CEO Ron Rocca, CFO Kamal Adawi, and COO Mark Hazeltine, at 4:30 PM ET. Investors can access the call via phone or webcast, with a replay available until March 29, 2022. Exagen focuses on providing innovative autoimmune testing solutions aimed at improving patient care for diseases like rheumatoid arthritis and lupus.

Positive

• Scheduled earnings release may indicate financial transparency.
• Focus on innovative testing solutions could enhance market position.

Negative

• No specific financial metrics or guidance were provided.

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2021 after the market close on Tuesday, March 22, 2022. Ron Rocca, Exagen’s President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT).

Interested parties may access the conference call by dialing (877) 407-3982 (U.S.) or (201) 493-6780 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.

A replay of the conference call will be available until Tuesday, March 29, 2022 at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 13727619. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately 30 minutes after the call concludes.

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. For further information please visit www.exagen.com.

CONTACTS:

Investor Relations
Exagen Inc.
Ryan Douglas
rdouglas@exagen.com  
760.560.1525

Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com 
760.477.5514

FAQ

What date will Exagen (XGN) release its financial results?

Exagen will release its financial results on March 22, 2022.

What time is the earnings call for Exagen (XGN)?

The earnings call is scheduled for 4:30 PM ET.

How can I access the Exagen (XGN) conference call?

You can access the conference call by dialing (877) 407-3982 for U.S. callers or (201) 493-6780 for international callers.

Will there be a replay of Exagen's (XGN) earnings call?

Yes, a replay will be available until March 29, 2022.

What is Exagen's focus in the healthcare market?

Exagen focuses on transforming care for autoimmune diseases through innovative testing solutions.